Business Context and Reporting Period
This Form 6-K filing by Check-Cap Ltd. (referred to as Mbody AI Ltd. in metadata) covers the period ending December 13, 2018. The registrant is a foreign private issuer based in Israel. The filing primarily serves to incorporate a press release regarding regulatory progress for the Company's C-Scan® technology.
Key Financial Metrics
The filing text does not provide specific financial data. There are no reported figures for revenue, profit, cash flow, margins, debt, or liquidity in this document.
Material Changes
The material event reported is the receipt of conditional approval from the U.S. Food and Drug Administration (FDA) for an Investigational Device Exemption (IDE). This approval allows the Company to initiate a U.S. pilot study of its C-Scan® device.
Guidance, Outlook, and Risks
The filing incorporates a press release containing "Forward Looking Statements" by reference. The primary outlook is the commencement of the U.S. pilot study. No specific financial guidance, risk factors, or contingencies are detailed within the body of this Form 6-K text.
Investor Verification Checklist
- Verify the full text of the press release (Exhibit 99.1) for details on the FDA IDE conditions and study parameters.
- Confirm the current status of the C-Scan® pilot study and any subsequent regulatory updates.
- Review the Company's most recent Form 20-F for actual financial performance and liquidity status, as this filing contains none.
- Check for any updates regarding the incorporation of this press release into the referenced Form S-8 and Form F-3 registration statements.